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Abstract
Background: Highly pathogenic avian influenza (HPAI) H5N1 viruses and their transmission capability from birds to humans
have raised global concerns about a potential human pandemic. The inherent nature of antigenic changes in influenza
viruses has not been sufficiently taken into account in immunogen designs for broadly protective HPAI H5N1 vaccines.
Methods: We designed a hyperglycosylated HA vaccine using N-linked glycan masking on highly variable sequences in the
HA1 globular head. Immunization of these hyperglycosylated HA DNA vaccines followed by a flagellin-containing virus-like
particle booster in mice was conducted to evaluate neutralizing antibody responses against various clades of HPAI H5N1
viruses.
Results: We introduced nine N-X-S/T motifs in five HA1 regions: 83NNT, 86NNT, 94NFT, 127NSS, 138NRT, 156NTT, 161NRS,
182NDT, and 252NAT according to sequence alignment analyses from 163 HPAI H5N1 human isolates. Although no
significant differences of anti-HA total IgG titers were found with these hyperglycosyalted HA compared to the wild-type
control, the 83NNT and 127NSS mutants elicited significantly potent cross-clade neutralizing antibodies against HPAI H5N1
viruses.
Conclusions: This finding may have value in terms of novel immunogen design for developing cross-protective H5N1
vaccines.
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Introduction
Highly pathogenic avian influenza (HPAI) H5N1 viruses and
their transmission capability from birds to humans have raised
global concerns about a potential human pandemic, with new
H5N1strains emerging and evolving. The World Health Organi-
zation (WHO) has classified recently isolated H5N1 viruses into 10
clades or sublineages, based on phylogenetic analysis of viral
hemagglutinin (HA) sequences [1]. With the ongoing threat of an
influenza pandemic arising from avian reservoirs, the development
of broadly protective vaccines is particularly important. To date,
such vaccines have been achieved such as using novel adjuvant
formulations [2].
However, the inherent nature of antigenic changes in influenza
viruses has not been sufficiently taken into account in immunogen
designs for broadly protective H5N1 vaccines. One approach is to
refocus antibody responses by designing immunogens that can
preserve overall immunogen structure, but selectively mutate
‘‘undesired’’ antigenic sites that are highly variable (i.e., mutants
that evade protective immune responses), immunosuppressive (i.e.,
downregulate immune responses to infections), or cross-reactive
(i.e., immune responses induce reactions to proteins resembling
immunogen) [3–9]. By refocusing antibody responses, the
immunogen design has been applied to HIV-1 vaccines- that is,
hyperglycosylated HIV-1 gp120 immunogens have been used,
with undesired epitopes masked by the selective incorporation of
N-linked glycans [4,6,10–12]. This glycan-masking strategy has
also been used in the design of vaccines aimed at enhancing
antibody responses to a broad range of H3N2 intertypic viruses
[13]. However, to date there are no reports for glycan-masking
immunogens for H5N1 vaccines.
DNA vaccines offer advantages in terms of genetic antigen
design, manufacturing time, stability in the absence of cold chains
and immunogenicity elicited by T cells via endogenerous antigen
processing pathways [14]. The problem of low DNA immunoge-
nicity in large animals and humans has been overcome through
the use of novel delivery systems such as gene-guns and
electroporation [14]. Furthermore, DNA vaccine-elicited immune
responses can be augmented by heterologous prime-boost
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vaccine format containing identical or similar antigens. DNA
vaccine prime-boost immunization strategies have been described
for inactivated influenza viruses [15,16], live-attenuated influenza
viruses [17], recombinant adenoviruses [18], virus-like particles
(VLPs) [19,20] and recombinant subunit proteins in adjuvants
[21–25]. Humans receiving H5 DNA vaccine priming followed by
a booster with an inactivated H5N1 vaccine were found to
enhance the protective antibody responses, and in some cases
induce hemagglutinin stem-specific neutralizing antibodies [16].
For this study we designed a hyperglycosylated HA vaccine
using N-linked glycan masking on highly variable sequences in the
HA1 globular head. Priming with hyperglycosylated HA DNA
vaccine followed by a booster of flagellin-containing influenza
virus-like particles (FliC-VLPs) in mice. FliC is a Toll-like receptor
5 (TLR-5) ligand and has been widely used for vaccine design, for
its ability to induce the innate immune effectors, like cytokine and
nitric oxide, e.g. induction of macrophage nitric oxide production
[26] and activation of interleukin-1 receptor-associated kinase
[27], thereby stimulating the activation of adaptive immune
response. We previously reported that the influenza VLP can be
fabricated by M2 fusion with FliC to improve and broaden the
elicited neutralizing antibodies against homologous and heterol-
ogous HPAI H5N1 viruses [28]. We hope these findings have
value in terms of novel immunogen design for developing cross-
protective H5N1 vaccines.
Materials and Methods
DNA-HA vaccine vector construction
Complimentary DNA (cDNA) from the HA gene of the A/
Thailand/1(KAN-1)/2004/H5N1 influenza virus (clade 1) was
generously provided by Prasert Auewarakul of Siriraj Hospital,
Thailand. A full-length HA sequence was inserted into
a pcDNA
TM3.1(+) vector (Invitrogen) via a KpnI/NotI cut site.
The HA-containing plasmid was transfected into 293 cells using
Turbofect reagent (Fermentas). At 48 h post-transfection, cell
lysates were collected by centrifugation at 5000 rpm for 10 min-
utes, and HA expression was analyzed by Western blotting using
anti-H5N1 HA antibodies (ab21297; Abcam).
HA glycosylation patterns and trypsin treatment
To characterize HA glycosylation patterns, 293 cells were
harvested following transfection with DNA-HA vectors for 48 h.
Cell lysates were treated with Endo H or PNGase F for 2 h at
37uC, and HA glycosylation patterns were determined by Western
blotting. For trypsin treatment, cell lysates were incubated with
trypsin for 30 min on ice, and HA0 cleavage into HA1 and HA2
was confirmed by Western blotting.
FliC-VLP preparation
FliC-VLPs were prepared as described previously [26] Briefly,
HA and M1 were cloned into one pFastBac
TM dual vector
(Invitrogen). NA and FliC-M2 (expressing FliC-M2 fusion
proteins) were cloned into the other pFastBac
TM dual vector.
Two recombinant baculoviruses were obtained to infect Sf9 cells
(Invitrogen) for FliC-VLPs production. Cell culture supernatants
were harvested at 72 h post-infection and concentrated by
filtration using a 500 kDa filter membrane. Concentrates were
loaded onto 0–60% sucrose gradients and centrifuged for 4 h at
33,000 rpm. Particles were measured by Western blotting using
the following antibodies: anti-H5N1 HA antibodies (ab21297;
Abcam), anti-NA antibodies (ab70759; Abcam), anti-M1 anti-
bodies (ab25918; Abcam), and anti-M2 antibodies (NB100–2073;
Novus). Particles were also observed by transmission electron
microscopy (TEM) as described previously [26].
Hyperglycosylated HA preparation
Mutations were introduced into the HA gene by site-directed
mutagenesis, with plasmids encoding a wild-type HA gene (i.e. A/
Thailand/1(KAN-1)/2004) used as templates. PCR reactions
(50 mL) were performed using 100 ng templates, 2 mM primer
pair, 200 mM dNTPs, and 2U of DNA polymerase. PCR
products were purified and treated with DpnI for 2 h at 37uC.
DpnI treated products were transformed into TOP10 competent
cells prior to the mutated plasmids.
Hemadsorption assay
293 cells (BCRC, FIRDI, Taiwan) were transfected with wild-
type and mutated DNA-HA vectors; cells were harvested 72 h post
infection. After washing with phosphate-buffered saline (PBS),
0.5% turkey red blood cells (RBCs) were added to cover the cell
monolayer, followed by incubation for 30 min at room temper-
ature. RBC adsorption was observed after two rinses with PBS.
Mouse immunization
A homologous/heterologous prime-boost regimen was used to
immunize female BALB/c mice (6–8 weeks old) with 50 mgo f
DNA and 30 mg of purified FliC-VLPs mixed with Alum adjuvant
in PBS. Immunizations were performed by intramuscular injection
during weeks 0 and 3 for the two-dose regimens, and weeks 0, 3,
and 5 for three-dose regimens. Blood was collected and serum
isolated 14 d after the final booster dose. Serum samples were
inactivated by incubation at 56uC for 30 min and stored at
220uC. All experiments were conducted in accordance with
Figure 1. Total anti-HA IgG titers elicited by DNA-HA and FliC-
VLPs. BALB/c mice were immunized using a prime boost regimen over
a three-week interval as shown: (i) FliC-VLP+FliC-VLP, (ii) DNA-HA+DNA-
HA, or (iii) DNA-HA+FliC-VLP. Sera were collected two weeks following
the booster immunization. Results indicate significantly higher HA-
specific IgG titers from DNA-HA vaccine vector priming followed by
FliC-VLP boosting. Shown are individual titers (points) and geometric
means (lines) for each group. Asterisks (*) indicate statistical significance
at p,0.05.
doi:10.1371/journal.pone.0039075.g001
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National Tsing Hua University (NTHU). Animal use protocols
were reviewed and approved by the NTHU Institutional Animal
Care and Use Committee (approval no. 09733).
Enzyme-linked immunosorbent (ELISA) assay
Recombinant HA proteins were obtained from baculovirus-
infected Sf9 cells and ELISA assays were performed as described
previously [29]. Briefly, 2 mg/mL of purified HA proteins were
coated onto 96 well plates and blocked with BSA. Serial dilutions
of each serum sample were incubated in the plates for 1 h at 37uC
and removed by 3 more washes with PBST. Goat anti-mouse IgG
conjugated HRP (Bethyl Laboratories, Inc.) was incubated in the
plates for 1 h at 37uC followed by 3 more washes with PBST.
Following reaction with TMB substrate, stop solution, plates were
read at 450 nm absorbance. End-point titers were determined as
reciprocals of final dilutions, giving an optical of two-fold
absorbance of negative control.
Hemagglutination inhibition (HI) and neutralization (NT)
assays
HI and NT assays were performed as described previously
[29,30]. For the HI assay, serum samples (two-fold dilutions
starting with an initial dilution of 1:10) were incubated with four
Figure 2. HI and NT titers against the NIBRG-14 virus. Neutralizing activities in sera collected from immunized mice were determined by
measuring (A) HI and (B) NT titers against the NIBRG-14 (clade 1) H5N1 influenza virus. Results showed that the DNA-HA vector priming/FliC-VLP
booster regiment elicited the highest magnitude of neutralizing antibodies. For calculation purposes, undetectable titers were scored as 1. Individual
titers (points) and geometric means (lines) are given for each group.
doi:10.1371/journal.pone.0039075.g002
Figure 3. HA sequence alignment. Results from analyses of amino acid variation in the HA1 of 163 avian influenza virus strains reveal five regions
with the highest variability scores (0 to 4 based on Vector NTI Tables). HA1 subunit regions A (HA81–101), B (HA125–144), C (HA150–166), D (HA182–
204), and E (HA245–257) were found to have higher scores.
doi:10.1371/journal.pone.0039075.g003
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agglutination inhibition was scored. Serum titers were expressed as
the reciprocals of the highest dilutions showing complete HA
inhibition. For the NT assay, 200 TCID50 of virus per well were
incubated with two-fold-diluted mice sera (starting dilution 1:40).
Virus and serum mixtures were transferred to MDCK cell (BCRC,
FIRDI, Taiwan) monolayers and incubated for 4 d at 37uC.
Neutralizing titers were defined as the reciprocals of highest serum
dilutions at which H5N1 virus infectivity was neutralized in 50%
of the wells. Infectivity was determined by the presence of
cytopathy on day 4; titers were calculated using the Reed-Muench
method.
H5 pseudotyped particle (H5pp) neutralization assay
Influenza lentiviral pseudotyped viruses were generated as
described previously [29]. Briefly, 293 cells were co-transfected
with pNL Luc E
2 R
2 and pcDNA3.1(+) expressing HA from A/
Hubei/1/2010 (clade 2.3.2) and A/Anhui/1/2005 (clade 2.3.4)
strains. Vibrio cholerae neuraminidase (6.2 mU/mL; Sigma) was
added 24 h post-transfection to release particles from cells. Culture
supernatants were collected and concentrated 48 h post-trans-
fection. H5pp titers were determined by p24 ELISA (Clontech).
Neutralizing antibodies were quantified as reduced luciferase
expression level following H5pp transduction in MDCK cells.
MDCK cells (10,000 cells/well) were seeded in 96-well plates in
100 mL DMEM. The following day, H5pp (,10
5RLU) was
Figure 4. Hyperglycosylated DNA design. Site-directed mutagenesis in five HA1 subunit regions (A, B, C, D, E) was performed following the
addition of N-linked glycosylation sites. Nine N-X-S/T motifs were created in the five regions: (1) 83NNT, (2) 86NNT, (3) 94NFT, (4) 127NSS, (5) 138NRT,
(6) 156NTT, (7) 161NRS, (8) 182NDT, (9) 252NAT. Triplet amino acids are underlined. Arrows point away from wild-type sequences to amino acid
changes resulting in N-linked glycosylation sequences.
doi:10.1371/journal.pone.0039075.g004
Figure 5. Hemadsorption assay. RBCs were added to 293 cells transfected with mutated DNA-HA vectors to cover cell monolayer. Results for RBC
adsorption indicate that cells transfected with the 83NNT, 86NNT, 94NFT, 127NSS, 138NRT and 161NRS vectors retained their hemadsorption
function, while cells transfected with the 156NTT, 183NDT and 252NAT vectors did not. Cells transfected with a wild-type DNA-HA vector were used
as a positive control (PC); cells tranfected with an empty vector were used as a negative control (NC).
doi:10.1371/journal.pone.0039075.g005
H5N1 Vaccine with Hyperglycosylated HA DNA and VLP
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37uC in 110 mL DMEM. Next, 100 mL of the resulting mixture
were transferred to cells. Fresh medium was added again after
24 h; luciferase assays were performed 48 hr later via the direct
addition of neolite luciferase substrate (PerkinElmer). Neutraliza-
tion titers and corresponding standard deviations were determined
from neutralization curves using the ID50 program (http://www.
ncbi.nlm.nih.gov/CBBresearch/Spouge/html_ncbi/html/index/
software.html) developed by John Spouge of the National Center
for Biotechnology Information, National Library of Medicine, US
National Institutes of Health.
Statistic analysis
All results were analyzed using two-tailed Student’s t tests, with
statistical significance indicated at p,0.05.
Results
Prime-boost immunization regimens
To investigate the combinatory use of DNA-HA vaccine vector
and influenza VLP for prime-boost immunization studies, we
immunized BALB/c mice intramuscularly with two doses within
a three-week interval, following the prime-boost regiments (i)
PBS+PBS, (ii) FliC-VLP+FliC-VLP, (iii) DNA-HA+DNA-HA, (iv)
DNA-HA+FliC-VLP. FliC-VLPs were obtained from bacuclovirus
coexpression of influenza HA, NA, M1 and FliC-M2 fusion
proteins since the FliC-VLPs have been shown to be more
immunogenic than influenza VLPs as we previously reported [28].
Groups of BALB/c mice were immunized with each specified
prime-boost regimen and their serum samples were collected two
weeks following the second dose. The results show that the HA-
specific total IgG titer resulting from DNA-HA vaccine vector
priming followed by FliC-VLP boosting was significantly higher
than from two-dose immunization regimen using a DNA-HA
vector and FliC-VLPs (Fig. 1). According to neutralizing activities
(as indicated by measuring HI and NT titers against the NIBRG-
14 [clade 1] vaccine virus), the DNA-HA vector priming/FliC-
VLP boosting regiment elicited the highest levels of neutralizing
antibodies (Fig. 2A–B). To further improve the immunization
protocols, DNA-HA vector was used for immunization for two
doses to enhance the DNA vaccine-elicited immunity, then
followed with a third booster dose of FliC-VLPs. The three-dose
immunization regimens (DNA-HA+DNA-HA+FliC-VLP) were
chosen for latter experiments.
Hyperglycosylated HA DNA design based on H5N1
human isolate amino acid sequences
To design the hyperglycosyalted HA DNA vaccines, we
performed sequence alignment analyses from 163 HPAI H5N1
human isolates, using sequences retrieved from the NCBI
Database. Amino acid differences were scored as 4, different
amino acid); 2, weakly similar amino acid; 1, strongly similar
amino acid; and 0, identical amino acid, as characterized by
Vector NTI tables. Using the alignment plot shown in Fig. 3, we
identified five regions that had higher scores, including regions A
(HA81–101), B (HA125–144), C (HA150–166), D (HA182–204),
and E (HA245–257). To design antibody-refocused immunogens,
we performed site-directed mutagenesis in each of the five regions,
with mutations that supported the addition of an N-X-S/T motif
(for the N-linked glycosylation site) but avoid receptor binding sites
(i.e. the B and D regions) [31,32]. Accordingly, we intrduced nine
N-X-S/T motifs in five HA1 regions: 83NNT, 86NNT, 94NFT,
127NSS, 138NRT, 156NTT, 161NRS, 182NDT, and 252NAT
(Fig. 4).
Figure 6. Hyperglycosylated HA characterization. Cell lysates from 293 cells transfected with hyperglycosylated DNA-HA vectors were treated
with PNGase F to determine changes in HA molecular weights. HA mutant proteins expressed by the DNA-HA vectors with added N-linked glycans
(83NNT, 86NNT, 94NFT, 127NSS, 138NRT and 161NRS) all had increased molecular weights that decreased following PNGase F treatment.
doi:10.1371/journal.pone.0039075.g006
Figure 7. Total anti-HA IgG titers elicited by hyperglycosylated
DNA vaccine priming followed by FliC-VLP boosting. Mice were
immunized with each immunorefocusing HA vector twice followed with
a third boosting dose with FliC-VLPs on a three-week interval. Sera were
collected at 2 weeks after final immunization, and determined the anti-
HA IgG titers by ELISA. The results showed that no significant
differences of the HA-specific total IgG titers of all the immunized
groups with the hyperglycosyalted HA DNA vaccines compared to the
wild-type control. Individual titers (points) and geometric means (lines)
are given for each group.
doi:10.1371/journal.pone.0039075.g007
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Refocused hyperglycosylated HA genes containing these eight
specified N-linked glycosylation sites were cloned into the DNA-
HA vaccine vector. Only the 83NNT, 86NNT, 94NFT, 127NSS,
138NRT and 161NRS mutant DNA-HA vectors retained the
hemagglutination property for turkey RBCs following transfection
into 293 cells (Fig. 5). These six HA mutant genes (83NNT,
86NNT, 94NFT, 127NSS, 138NRT and 161NRS) were further
confirmed for the introduction of N-linked glycans in HA antigens,
Figure 8. HI and NT titers against the NIBRG-14 and A/whooper swan/Mongolia/244/2005 viruses. Neutralizing activity in sera collected
from immunized mice was determined by measuring (A) HI and (B) NT titers against the A/Vietnam/1194/2004 (clade 1) H5N1 virus, and (C) HI and (D)
NT titers against the A/Whooper Swan/Mongolia/244/2005 (clade 2.2) H5N1 virus. For calculation purposes, an undetectable level was scored as
titer=1. Individual titers (points) and geometric means (lines) are given for each group. Asterisks indicate statistical significance at p,0.05.
doi:10.1371/journal.pone.0039075.g008
Figure 9. Neutralization against H5pp of A/Anhui/1/2005 and A/Hubei/1/2010 strains. Dose-dependent neutralization curves were plotted
against (A) A/Anhui/1/2005 and (B) A/Hubei/1/2010 H5N1 influenza strains. Data indicate that the 83NNT and 127NSS HA mutants elicited higher
neutralizing antibodies than the wild-type HA.
doi:10.1371/journal.pone.0039075.g009
H5N1 Vaccine with Hyperglycosylated HA DNA and VLP
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same molecular weight following treatment with PNGase F (Fig. 6).
Antibodies elicited by hyperglycosylated HA DNA
vaccines
To investigate antibody responses elicited by the six hypergly-
cosylated HA mutants, over three weeks we immunized mice with
two doses of DNA-HA vector, and followed with a third booster
dose with FliC-VLPs. The three-dose immunization strategy
(DNA-HA+DNA-HA+FliC-VLP) was applied to improve the
DNA vaccine-elicited immune responses by heterologous prime-
boost immunization. Our results indicate no significant differences
of anti-HA total IgG titers across the immunized groups, with
hyperglycosyalted HA DNA vaccines compared to the wild-type
control (Fig. 7). However, for the elicitation of functional
antibodies, the 83NNT HA mutant was found to have a higher
HI titer (p,0.05) (Fig. 8A) but only slightly higher but not
statistically significant NT titer (Fig. 8B) against the NIBRG-14
vaccine virus, a vaccine strain virus derived from a reassortant
H5N1 vaccine strain containing modified HA and NA from the
A/Vietnam/1194/2004 H5N1 virus (clade 1 strain). We also
measured HI and NT titers in these sera against the A/Whooper
Swan/Mongolia/244/2005 H5N1 virus (clade 2.2 strain). The
data (presented as cross-clade functional antibodies) indicate that
the 127NSS HA mutant elicited a higher HI titer (p,0.05)
(Fig. 8C) and the 83NNT and 127NSS HA mutants elicited higher
NT titers (p,0.05) (Fig. 8D). To further confirm the cross-clade
neutralizing antibodies, H5pp containing the HA gene of A/
Anhui/1/2005 (clade 2.3.4) or A/Hubei/1/2010 (clade2.3.2) was
reacted with the serum samples from wild-type, 83NNT, and
127NSS HA immunizations. Dose dose-dependent neutralization
curves were all shown for H5pp Anhui (Fig. 9A) and H5pp Hubei
(Fig. 9B), showing the cross-clade neutralizing antibodies elicited
by the 83NNT HA followed by 127NSS HA immunizations were
significantly higher compared to wild-type HA immunization.
Combined, the data show that the 83NNT and 127NSS mutants
elicit potent cross-clade neutralizing antibodies against HPAI
H5N1 viruses.
Discussion
As H5N1 viruses evolve and diverge into distinct antigenic
clades and subclades, the growing challenge is to develop vaccines
that can provide broad protective immunity. The WHO has
recently recommended 8 H5N1 virus clades/subclades (1, 2, 2.1,
2.2.1, 2.2.3, 2.3.4, 4, 7) as candidates for vaccine preparation [33].
In this study we designed hyperglycosylated HA and used the
hyperglycosylated HA DNA as a prime-boost immunization
regimen with FliC-VLPs. Immunofocusing antibody responses
by priming with the hyperglycosylated HA DNA vaccine plus
additional glycan masking at 83-NNT or 127-NNS in the HA1
globular head induced more potent cross-clade neutralizing
antibodies against HPAI H5N1 viruses.
A prime-boost immunization regimen represents a straightfor-
ward strategy for augmenting immune responses elicited by DNA
vaccination. Our results demonstrate that priming with a DNA-
HA vaccine followed by a booster of FliC-VLPs induced higher
titers of total IgG and functional HI and NT antibodies compared
to an immunization regimen of two doses of either DNA or FliC-
VLPs along (Fig. 2A–B). Notably, serum samples in the FliC-
VLP+FliC-VLP group showed all high binding titers of (10
5 IgG
titers in Fig. 1) but only few individual samples showed HI and NT
titers (Fig. 2). The immunizations using influenza VLPs or FliC-
VLPs required three doses under our experimental conditions to
give all high HI and NT titers where the binding titers reached to
approximately 10
6 IgG titers (data not shown). The heterologous
prime-boost regimen consisting of DNA and HIV-gag VLPs have
previously been reported as eliciting higher neutralizing antibodies
and greater protective immunity against H5N1 and other seasonal
influenza viruses [19,20]. Our results are in agreement with these
findings in that the highest levels of neutralizing antibody titers
were elicited by DNA-VLP heterologous prime-boost immuniza-
tion regardless of which influenza FliC and VLP types were used.
Glycan masking on the immunodominant epitopes of surface
immunogens can elicit more broadly neutralizing antibodies if
immunodominant sites overlap with the sequence variable regions
of antigenic sites. We therefore hypothesized that hyperglycosy-
lated HA with extra glycan masking on the HA1 variable regions
(A–E in Fig. 3) might boost broadly neutralizing antibodies against
HPAI H5N1 viruses. Our results indicate that hyperglycosyalted
HA DNA vaccines containing 83NNT mutation in the HA1
globular head resulted in the elicitation of a higher HI titer against
the homologous clade virus (A/Vietnam/1194/2004, clade 1)
(Fig. 8A–B). Furthermore, hyperglycosyalted HA DNA vaccines
containing 83NNT or 127NSS mutation elicited higher NT titers
against the heterologous clade virus (A/whooper swan/Mongolia/
244/2005 strain, clade 2.2) (Fig. 8C–D). The 83NNT HA mutant
also shows the highest levels of neutralizing antibodies against
H5pp of two heterologous clade viruses (A/Anhui/1/2005 strain,
clade 2.3.4; A/Hubei/1/2010 strain, clade 2.3.2) (Fig. 9A–B). The
results were obtained by two-dose priming with DNA-HA vector
(hyperglycosylated HA mutants) and a third booster dose of FliC-
VLPs that only contained the wild type HA. Using the FliC-VLPs
containing only 83NNT and/or 127 NNS mutant HA antigen(s)
as the third booster dose should further improve the elicited
neutralizing antibody responses against HPAI H5N1 viruses.
The 83NNT mutation is located at the Cb antigenic site, and
the 127NNS mutation is close to the Sa antigenic site of the HA of
H5N1 human isolates, based on the H1N1 antigenic map [34,35].
Glycan masking of these two sites may refocus polyclonal antibody
responses to other antigenic sites of HA molecules. Recent studies
have revealed that the cross-neutralizing epitopes of influenza
viruses were mapped to either the F subdomain of HA2 stem
[36,37], or close to the receptor binding site [38,39], the Ca2 site
of H1N1 [38], as well as the A and B site/sites of H3N2 HA [40].
Since the HA1 globular head contains immunodominant epitopes
that overlap with the extensive antigen variation sites compared to
the non-overlapping of the poorly immunogenic HA2 stem region
[41]. The mechanisms of glycan masking on 83NNT and 127NSS
residues to enhance functional antibodies against homologous and
heterologous clades of HPAI H5N1 viruses require further
investigation.
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